RLAY insider trading
NasdaqGM HealthcareRelay Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Company website: www.relaytx.com
RLAY insider activity at a glance
FilingIQ has scored 366 insider transactions for RLAY since Jul 20, 2020. The most recent filing in our index is dated May 14, 2026.
Across the full history, 5 open-market purchases
and 252 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on RLAY insider trades is 57.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest RLAY Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding RLAY
Frequently asked
- How many insider trades does FilingIQ track for RLAY?
- FilingIQ tracks 366 Form 4 insider transactions for RLAY (Relay Therapeutics, Inc.), covering filings from Jul 20, 2020 onwards. 9 of those were filed in the last 90 days.
- Are RLAY insiders net buyers or net sellers?
- Across the full Form 4 history for RLAY, 5 transactions (1%) were open-market purchases and 252 (69%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RLAY insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is RLAY in?
- Relay Therapeutics, Inc. (RLAY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.93B.
Methodology & sources
Every RLAY insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.